NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?

被引:42
作者
Yilmaz, Yusuf [1 ,2 ]
机构
[1] Marmara Univ, Dept Gastroenterol, Sch Med, Istanbul, Turkey
[2] Marmara Univ, Inst Gastroenterol, Istanbul, Turkey
关键词
nonalcoholic fatty liver disease; metabolic syndrome; risk factors; hemoglobin; NONALCOHOLIC FATTY LIVER; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; LIPID-METABOLISM; HEMATOCRIT; HEMOGLOBIN; INFLAMMATION; ASSOCIATION;
D O I
10.1055/s-0032-1306422
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that have been associated with an increased risk of developing nonalcoholic fatty liver disease (NAFLD). Insulin resistance and central obesity are the key components of MetS, ultimately leading to liver fat accumulation and the subsequent development of necroinflammatory liver injury. However, the origin and nature of the metabolic stressors responsible for stimulating the progression of simple steatosis to nonalcoholic steatohepatitis (NASH) remain to be clearly identified. In addition, epidemiologic research on the association between MetS and NAFLD has provided only limited information to guide the development of targeted interventions, in particular, nutrition and pharmacologic prevention programs. This review summarizes the evidence supporting the proposal that NAFLD is not invariably associated with the presence of MetS, and mechanisms other than insulin resistance may contribute to the chronic inflammatory processes that underpin the development of liver fat accumulation and the subsequent architectural distortion of the liver. A special focus is given to increased hemoglobin as a risk factor for the development of NAFLD in the absence of MetS.
引用
收藏
页码:14 / 21
页数:8
相关论文
共 83 条
[1]  
Abdeen Mohammad Bosem, 2006, J Cardiometab Syndr, V1, P36, DOI 10.1111/j.0197-3118.2006.05523.x
[2]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[3]   Current treatment of non-alcoholic fatty liver disease [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DIABETES OBESITY & METABOLISM, 2009, 11 (03) :188-195
[4]   Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease [J].
Aktas, Bilge ;
Yilmaz, Yusuf ;
Eren, Fatih ;
Yonal, Oya ;
Kurt, Ramazan ;
Alandab, Yesim Ozen ;
Celikel, Cigdem Ataizi ;
Ozdogan, Osman ;
Imeryuz, Nese ;
Kalayci, Cem ;
Avsar, Erol .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (04) :544-549
[5]   Redox reactions of hemoglobin and myoglobin: Biological and toxicological implications [J].
Alayash, AI ;
Patel, RP ;
Cashon, RE .
ANTIOXIDANTS & REDOX SIGNALING, 2001, 3 (02) :313-327
[6]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[7]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[8]  
2-S
[9]   Metabolic syndrome and non-alcoholic fatty liver disease [J].
Almeda-Valdes, Paloma ;
Cuevas-Ramos, Daniel ;
Aguilar-Salinas, Carlos Alberto .
ANNALS OF HEPATOLOGY, 2009, 8 :S18-S24
[10]  
Beck-Nielsen H, 1999, DRUGS, V58, P75